MiR-206 has also directly targeted the oncogenes KRAS and annexin a2 (ANXA2), acting as a tumor suppressor in various types of cancer by blocking cell cycle progression, cell proliferation, migration, and invasion. Here, KRAS is linked to neoplasm.